<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03710902</url>
  </required_header>
  <id_info>
    <org_study_id>HUS/53/2017</org_study_id>
    <secondary_id>TYH2016127</secondary_id>
    <nct_id>NCT03710902</nct_id>
  </id_info>
  <brief_title>Empowerment and Mobile Technology in the Control of Cardiovascular Risk Factors in Patients With Ischemic Stroke</brief_title>
  <acronym>CARDIOSTROKE</acronym>
  <official_title>Empowerment and Mobile Technology in the Control of Cardiovascular Risk Factors in Patients With Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jukka Putaala</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital District of Helsinki and Uusimaa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CARDIOSTROKE is a randomized trial comparing mobile-device assisted control of&#xD;
      hypertension together with screening of occult atrial fibrillation to standard care in&#xD;
      patients with recent ischemic stroke or transient ischemic attack.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) and hypertension are among the main treatable risk factors for&#xD;
      ischemic stroke and transient ischemic attack (TIA). Detecting paroxysmal atrial fibrillation&#xD;
      in stroke patients is challenging, but highly relevant since anticoagulation can effectively&#xD;
      reduce the risk of recurrent strokes. Furthermore, hypertension remains poorly controlled&#xD;
      even after stroke despite multiple available treatment options. In the CARDIOSTROKE trial,&#xD;
      the investigators aim to randomize 405 patients with recent ischemic stroke or TIA into (1)&#xD;
      standard diagnostic work-up, follow-up and treatment (control group) and (2) 3-week ECG&#xD;
      monitoring to detect occult AF and self-monitoring of blood pressure with&#xD;
      mobile-device-assisted self-titration of antihypertensive medication (intervention group).&#xD;
      Randomization will occur 2:1 into control and intervention groups. The co-primary outcomes&#xD;
      include (1) incidence of new-onset AF and (2) difference in the mean blood pressure at&#xD;
      12-months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2018</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Clinical endpoints will be assessed according to PROBE principles, i.e. outcomes assessors are masked to treatment allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with New Atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
    <description>New diagnosis of atrial fibrillation (&gt;30 s)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Blood Pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Mean change in systolic/diastolic blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with New Cardiovascular Events within 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Any of stroke, myocardial infarction, revascularization, or cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with New Cardiovascular Events within 36 Months</measure>
    <time_frame>36 months</time_frame>
    <description>Any of stroke, myocardial infarction, revascularization, or cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Costs</measure>
    <time_frame>36 months</time_frame>
    <description>Total direct healthcare costs</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events related to ECG monitoring, blood pressure home monitoring, and mobile-device assisted self-adjustment of blood pressure medication according to a pre-specified protocol.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Severe Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Severe adverse event related to mobile-device assisted self-adjustment of blood pressure medication according to a pre-specified protocol.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">405</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Transient Ischemic Attack</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Hypertension</condition>
  <condition>Empowerment</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard diagnostic work-up, follow-up, and treatment of hypertension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ECG monitoring for 3 weeks</intervention_name>
    <description>A 3-week continuous ECG monitoring to detect occult AF.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Self-monitoring of BP and self-titration of antihypertensive medication</intervention_name>
    <description>One-week monthly self-monitoring of BP and self-titration of antihypertensive medication according to a pre-specified protocol, assisted with a mobile device application.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ischemic stroke or transient ischemic attack (ABCD2 score ≥3)&#xD;
&#xD;
          -  Age ≥40 years&#xD;
&#xD;
          -  Pre-existing or newly diagnosed hypertension&#xD;
&#xD;
          -  Informed consent from the patient or legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known high-risk source of cardioembolism&#xD;
&#xD;
          -  Known indication for anticoagulation&#xD;
&#xD;
          -  Contraindication for anticoagulation&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  Non-compliance to study interventions as judged by the investigator&#xD;
&#xD;
          -  Serious condition hampering the study conduct&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tuomas Lumikari, MD</last_name>
    <phone>+35894711</phone>
    <email>tuomas.lumikari@helsinki.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anu Eräkanto</last_name>
    <email>anu.erakanto@hus.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terhi Saarikoski, RN</last_name>
      <phone>+35894711</phone>
      <email>terhi.saarikoski@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Tuomo Nieminen, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jukka Putaala, A/Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tuomas Lumikari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hyvinkää Hospital</name>
      <address>
        <city>Hyvinkää</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Terttu Heinkinheimo-Connell, MD, PhD</last_name>
      <email>terttu.heikinheimo-connell@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Toni Huttunen, MD</last_name>
      <email>toni.huttunen@hus.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kanta-Häme Central Hospital</name>
      <address>
        <city>Hämeenlinna</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiina Alapirtti, MD, PhD</last_name>
      <email>tiina.alapirtti@khshp.fi</email>
    </contact>
    <contact_backup>
      <last_name>Elina Laakso, MD</last_name>
      <email>elina.laakso@khshp.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Päijät-Häme Central Hospital</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuomo Nieminen, MD, PhD, Prof.</last_name>
      <email>tuomo.nieminen@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Anne Kerola, MD, PhD</last_name>
      <email>anne.m.kerola@phhyky.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lohja Hospital</name>
      <address>
        <city>Lohja</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markus Wiksten, MD, PhD</last_name>
      <email>markus.wiksten@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Hanna Kaltiainen, MD</last_name>
      <email>hanna-leena.kaltiainen@hus.fi</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 16, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital District of Helsinki and Uusimaa</investigator_affiliation>
    <investigator_full_name>Jukka Putaala</investigator_full_name>
    <investigator_title>Head of Stroke Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

